Publications by authors named "Patricia A English"
Aim: Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma.
Patients & Methods: Kaplan-Meier analysis of data from a randomized, Phase II study (n = 292) suggested baseline predictive value for circulating soluble Ang-2 and MMP-2 and HIF-1α percentage of tumor expression. Using this dataset, the sensitivity, specificity and area under the curve (AUC) were calculated, using receiver operating characteristic (ROC) curves.
Background: In the phase III axitinib second-line (AXIS) trial, axitinib significantly prolonged progression-free survival (PFS) versus sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Analyses of associations between germline single-nucleotide polymorphisms (SNPs) and outcomes are reported.
Patients And Methods: DNA samples from blood were genotyped using TaqMan allelic discrimination.
Article Synopsis
- The study aimed to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for the γ-secretase inhibitor PF-03084014 in patients with advanced solid tumors, while also assessing safety and initial effectiveness.
- The phase I trial involved 64 patients taking PF-03084014 orally, twice daily, with doses ranging from 20 to 330 mg, ultimately identifying the MTD as 220 mg and RP2D as 150 mg due to better safety.
- Results showed mild to moderate side effects, with some patients achieving significant tumor responses, indicating PF-03084014's potential for further development in cancer treatment.
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Cancer Chemother Pharmacol
October 2014
Purpose: Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a randomized phase II trial comparing sunitinib treatment schedules, separate exploratory biomarker analyses investigated the correlations of efficacy with selected serum, germ line single-nucleotide polymorphism (SNP), or tumor markers.
Methods: Advanced RCC patients received first-line sunitinib 50 mg/day on the approved 4-week-on-2-week-off schedule (n = 146) or 37.
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, and pharmacodynamics of the aurora kinase A and B inhibitor, PF-03814735. Patients with advanced solid tumours received oral, once-daily (QD) PF-03814735 on Schedule A: days 1-5 (5-100mg); or Schedule B: days 1-10 (40-60mg) of 21-day cycles.
View Article and Find Full Text PDF